News Sentiment

CTNM sentiment intelligence

Contineum Therapeutics, Inc. Class A Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 15.19 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

85/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend active

+0.6% over one week, +27.9% over four weeks, trend active, and near fair-value range.

Latest direct headline Positive

Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?

Market Reaction

Balanced read

51/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 85/100 classification
One-week reaction 0.6% Price digesting
Trend fit Trend active 27.9% over four weeks
Fair value 23.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 41
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 15
Market source 8
Investing.com 4
TradingView 4
The Globe and Mail 2
Investing.com Canada 2
Investing.com Nigeria 2
Business Wire 2

Event Lens

What the news is about

Classified themes
Market update 41
Earnings 17
Analyst action 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 60
Investing.com Direct company coverage

Contineum Therapeutics CSO Lorrain Daniel S. sells $16,640 in stock

Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, sold 1,040 shares of the company's Class A Common Stock for a total of $16,640 on July 8 and 9, 2026. These sales followed an exercise of stock options at a price of $1.01 per share and were conducted under a 10

Tone
Negative 40/100
Event
Market update
Published
11 Jul 2026 14:41
Source
Investing.com
Stock Titan Direct company coverage

Contineum Therapeutics (NASDAQ: CTNM) CSO sells 1,040 shares, exercises options

Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, exercised options for 1,040 shares at $1.01 each and subsequently sold those shares at $16.00 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted in September 202

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 21:40
Source
Stock Titan
Investing.com India Direct company coverage

Contineum Therapeutics CSO Lorrain Daniel S. sells $16,640 in stock By Investing.com

Daniel S. Lorrain, CSO at Contineum Therapeutics (NASDAQ:CTNM), sold $16,640 worth of Class A Common Stock after exercising stock options. These transactions, executed under a 10b5-1 trading plan, occurred as CTNM stock approached its 52-week high, with a 283% return over the pas

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 21:40
Source
Investing.com India
Stock Titan Direct company coverage

Contineum (CTNM) CEO sells 2,500 shares under Rule 10b5-1 plan

Contineum Therapeutics CEO Carmine N. Stengone exercised stock options for 2,500 shares at $1.01 per share and subsequently sold those 2,500 shares at $16.00 per share on July 8, 2026. These transactions, valued at $40,000 for the sale, were conducted under a pre-arranged Rule 10

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 22:40
Source
Stock Titan
Investing.com Direct company coverage

Contineum Therapeutics CEO Stengone sells $40,000 in shares

Carmine N. Stengone, CEO of Contineum Therapeutics, sold 2,500 shares of Class A Common Stock for $40,000, following the exercise of stock options. This transaction was executed under a pre-arranged 10b5-1 trading plan, occurring while the stock traded near its 52-week high and a

Tone
Negative 35/100
Event
Market update
Published
08 Jul 2026 22:40
Source
Investing.com
Investing.com South Africa Direct company coverage

Contineum Therapeutics CSO Daniel Lorrain sells $594,578 in stock By Investing.com

Contineum Therapeutics' Chief Scientific Officer, Daniel Lorrain, sold approximately $594,578 worth of company stock through multiple transactions on June 30 and July 1, 2026. These sales were conducted under a pre-arranged 10b5-1 trading plan and involved exercising stock option

Tone
Negative 39/100
Event
Market update
Published
03 Jul 2026 11:40
Source
Investing.com South Africa
Investing.com Canada Direct company coverage

Form 4 Contineum Therapeutics Inc For: 2 July By Investing.com

This article reports on a Form 4 filing for Contineum Therapeutics Inc. on July 2nd. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the ownership of company stock by company insiders. The article indica

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 11:13
Source
Investing.com Canada
Stock Titan Direct company coverage

Contineum (NASDAQ: CTNM) CSO sells 37,179 shares and exercises 33,009 options

Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, recently sold 37,179 shares of Class A Common Stock and exercised options for 33,009 shares. These transactions, conducted under a pre-arranged Rule 10b5-1 trading plan, took place on June 30 and July 1, 2026. A

Tone
Negative 28/100
Event
Market update
Published
02 Jul 2026 22:10
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Contineum Therapeutics CMO Tim Watkins sells $173,590 in company stock By Investing.com

Contineum Therapeutics' Chief Medical Officer, Tim Watkins, sold 10,833 shares of company stock for $173,590 after exercising stock options under a pre-arranged trading plan. This transaction occurred amidst a significant surge in the stock's value, which has gained almost 300% i

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 00:18
Source
Investing.com Nigeria
Investing.com Direct company coverage

Contineum Therapeutics CEO Stengone sells $160,080 in stock

Contineum Therapeutics CEO Carmine N. Stengone sold 10,000 shares of company stock for $160,080 and acquired 10,000 shares through option exercises for $10,725, both under a pre-arranged trading plan. These transactions occurred on June 30, 2026, with the sale happening near the

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 00:08
Source
Investing.com
Investing.com Nigeria Direct company coverage

Form 4 Contineum Therapeutics Inc For: 1 July By Investing.com

This article reports on a Form 4 filing for Contineum Therapeutics Inc (CTNM) for activity on July 1st. Form 4 filings are used to disclose changes in beneficial ownership of securities by company insiders. The article provides the title and source, indicating it's a routine fina

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 23:10
Source
Investing.com Nigeria
Stock Titan Direct company coverage

[Form 4] Contineum Therapeutics, Inc. Insider Trading Activity

Contineum Therapeutics CEO Carmine N. Stengone exercised stock options for 10,000 shares of Class A Common Stock and subsequently sold them in an open-market transaction at a weighted average price of $16.008 per share. These transactions were executed under a pre-arranged Rule 1

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 23:08
Source
Stock Titan
Stock Titan Direct company coverage

Contineum (NASDAQ: CTNM) CMO sells 10,833 shares after option exercise

Contineum Therapeutics, Inc.'s CMO & Head of Development, Tim Watkins, exercised stock options for 10,833 shares at $4.50 per share and subsequently sold them at a weighted average price of $16.0242 per share on June 30, 2026. This transaction was conducted under a Rule 10b5-1 tr

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 23:08
Source
Stock Titan
Investing.com Direct company coverage

Contineum Therapeutics CMO Tim Watkins sells $173,590 in company stock

Contineum Therapeutics' Chief Medical Officer, Tim Watkins, sold 10,833 shares of company stock for $173,590 after acquiring them through stock option exercises. These transactions were executed under a pre-arranged trading plan, coinciding with a significant surge in the stock's

Tone
Negative 40/100
Event
Market update
Published
01 Jul 2026 19:16
Source
Investing.com
Stock Titan Direct company coverage

[144] Contineum Therapeutics, Inc. SEC Filing

This SEC Form 144 filing by Contineum Therapeutics, Inc. details a proposed sale of 10,000 shares of common stock with an aggregate market value of $150,000. The shares were acquired on June 30, 2026, through the exercise of stock options and are intended to be sold through Morga

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 12:42
Source
Stock Titan
BioSpace Direct company coverage

Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry

Contineum Therapeutics announced the publication of a manuscript in the Journal of Medicinal Chemistry detailing the discovery and characterization of PIPE-791, a potent and brain-penetrant LPAR1 antagonist. This compound is currently in a global Phase 2 clinical trial for idiopa

Tone
Positive 74/100
Event
Market update
Published
01 Jul 2026 03:39
Source
BioSpace
Stock Titan Direct company coverage

Contineum Therapeutics (CTNM) grants director 19,000 stock options at $14.19

Contineum Therapeutics director Evert B. Schimmelpennink was granted stock options for 19,000 shares of Class A Common Stock at an exercise price of $14.19 per share under the company's 2024 Equity Incentive Plan. This is a compensation-related award, not an open-market purchase.

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 03:07
Source
Stock Titan
Investing.com Australia Direct company coverage

Contineum Therapeutics CEO Stengone sells $160,080 in stock By Investing.com

Carmine N. Stengone, CEO of Contineum Therapeutics (NASDAQ:CTNM), recently sold 10,000 shares of company stock for $160,080, with the transaction occurring through a pre-arranged 10b5-1 trading plan. On the same day, he acquired 10,000 shares by exercising stock options at a lowe

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 02:10
Source
Investing.com Australia
Stock Titan Direct company coverage

Contineum (CTNM) awards non-employee director 19,000 stock options

Contineum Therapeutics (CTNM) has granted 19,000 stock options to non-employee director Diego Miralles as part of its standard board compensation program. The options, with an exercise price of $14.19 per share, were awarded under the company's 2024 Equity Incentive Plan and vest

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 22:10
Source
Stock Titan
Stock Titan Direct company coverage

Contineum Therapeutics (CTNM) awards director 19,000-share stock option grant

Contineum Therapeutics (CTNM) director Olivia C. Ware received a grant of stock options for 19,000 shares of Class A common stock, with an exercise price of $14.19 per share. These options were issued under the 2024 Equity Incentive Plan as part of the non-employee director compe

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 21:39
Source
Stock Titan
Stock Titan Direct company coverage

Contineum Therapeutics (CTNM) director receives 19,000 stock options grant

Contineum Therapeutics director Lori Lyons-Williams was granted 19,000 stock options under the company’s 2024 Equity Incentive Plan. These options, tied to Class A Common Stock, have an exercise price of $14.19 per share and expire on June 25, 2036. The grant is part of the Non-E

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 21:39
Source
Stock Titan